# Advances in Biomimetic Nanoparticles for Targeted Cancer Therapy and Diagnosis

## TL;DR

This paper explores how biomimetic nanoparticles can improve cancer treatment by mimicking natural cells to avoid immune detection and deliver drugs more effectively.

## Contribution

The paper reviews recent advances in biomimetic nanoparticles for cancer therapy and highlights the need for clinical translation.

## Key findings

- Biomimetic nanoparticles can evade immune clearance and reduce toxicity.
- They offer improved drug targeting and biocompatibility in the tumour microenvironment.
- Current developments show promise for cancer imaging and treatment applications.

## Abstract

Biomimetic nanoparticles have recently emerged as a novel drug delivery platform to improve drug biocompatibility and specificity at the desired disease site, especially the tumour microenvironment. Conventional nanoparticles often encounter rapid clearance by the immune system and have poor drug-targeting effects. The rapid development of nanotechnology provides an opportunity to integrate different types of biomaterials onto the surface of nanoparticles, which enables them to mimic the natural biological features and functions of the cells. This mimicry strategy favours the escape of biomimetic nanoparticles from clearance by the immune system and reduces potential toxic side effects. Despite the rapid development in this field, not much has progressed to the clinical stage. Thus, there is an urgent need to develop biomimetic-based nanomedicine to produce a highly specific and effective drug delivery system, especially for malignant tumours, which can be used for clinical purposes. Here, the recent developments for various types of biomimetic nanoparticles are discussed, along with their applications for cancer imaging and treatments.